Skip to main content
Clinical Trials/NCT00749619
NCT00749619
Completed
Phase 3

Addition of Heparin to Taurolock-TM CLS in HD Patients With TCC Dose it Improve Catheter Patency Problems ?

Western Galilee Hospital-Nahariya1 site in 1 countryMay 2007

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
End Stage Renal Disease
Sponsor
Western Galilee Hospital-Nahariya
Locations
1
Status
Completed
Last Updated
17 years ago

Overview

Brief Summary

Addition of Heparin to the Catheter Lock Solution (CLS): Taurolock-TM will improve the vascular patency compared to Taurolock-TM alone , in hemodialysis patients with Tunneled Cuffed Catheter(TCC) as vascular access.

Detailed Description

Bacteremia and thrombosis are the major complications of TCC used for hemodialysis.Instilation of CLS containing antibiotic-anticoagulant solution in the end of each dialysis session till the next dialysis ,can prevent Catheter related bacteremia (CRB).In previous study in our department, Taurolock-TM decreased the rate of CRB but increased the incidence of catheter malfunction. The aim of the study is to investigate the influence of of Heparin addition to CLS-Taurolock- TM ( Taurolidine \&citrate 4%) in prevention of catheter patency problems in HD patients with TCC, in addition to CRB prevention. Methods : Patients with newly inserted TCC for HD enrolled and randomized to receive one of three CLS types : group 1- Taurolock-TM, Group 2 - Taurolock-TM and Heparin , Group 3- Heparin .Patients were followed for 6 monthes. The objective of the study is to investigate the effect of Taurolock TM with heparin on the rate of CRB and vascular patency.

Registry
clinicaltrials.gov
Start Date
May 2007
End Date
August 2008
Last Updated
17 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Hemodialysis patients with new TCC
  • Informed Consent

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Study Sites (1)

Loading locations...

Similar Trials